Puscas I, Coltau M, Baican M, Pasca R, Domuta G, Hecht A
Oradea Medical University, Romanian Medical Academy of Sciences, Center for Research and Medical Assistance, Simleu Silvaniei, Romania.
Drugs Exp Clin Res. 2001;27(2):53-60.
Carbonic anhydrase (CA) is a zinc enzyme that catalyses the reversible hydration reaction of CO2 and plays a major role in the acid-base balance. We have previously shown that certain vasoconstrictive therapeutic agents increase CA I activity whereas vasodilating drugs reduce the activity of this isozyme by a direct mechanism of action. In this paper we studied the effect of other vasoconstrictive and vasodilating agents on CA I activity in order to elucidate the involvement of vascular smooth muscle CA I in vasoconstrictive and vasodilating processes. We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits. In vivo, we selected six groups of five rabbits each, which were administered the following substances in acute experiments: orciprenaline (group 1), desmopressin (group 2), verapamil (group 3), irbesartan (group 4), acetazolamide (group 5) and placebo (control group). Vascular smooth muscle CA I activity and systolic blood pressure were determined and compared with those of the control group. In vitro results showed that all the vasoconstrictive agents studied increased purified and human erythrocyte CA I activity as well as vascular smooth muscle CA I, while vasodilating substances reduced the activity of isozyme by a direct mechanism of action. The same results obtained in vivo showed that activation of vascular smooth muscle CA I increased blood pressure while its inhibition reduced blood pressure. The results of this study suggest that pHi changes, induced by activating or inhibiting CA I in vascular smooth muscle, might be responsible for changes in vascular tonus.
碳酸酐酶(CA)是一种锌酶,催化二氧化碳的可逆水合反应,在酸碱平衡中起主要作用。我们之前已经表明,某些血管收缩治疗药物会增加CA I的活性,而血管舒张药物则通过直接作用机制降低这种同工酶的活性。在本文中,我们研究了其他血管收缩剂和血管舒张剂对CA I活性的影响,以阐明血管平滑肌CA I在血管收缩和舒张过程中的作用。我们研究了去甲肾上腺素、前列腺素F2α、血栓素A2、白三烯B4、血管紧张素II、血管加压素、吲哚美辛、哌唑嗪、肼屈嗪、可乐定、利血平、前列腺素I2、吲达帕胺、呋塞米、氨氯地平、维拉帕米和厄贝沙坦对纯化的人红细胞CA I和从兔子分离的血管平滑肌CA I的体外作用。在体内,我们选择了六组,每组五只兔子,在急性实验中给它们施用以下物质:奥西那林(第1组)、去氨加压素(第2组)、维拉帕米(第3组)、厄贝沙坦(第4组)、乙酰唑胺(第5组)和安慰剂(对照组)。测定血管平滑肌CA I活性和收缩压,并与对照组进行比较。体外结果表明,所有研究的血管收缩剂均增加了纯化的人红细胞CA I活性以及血管平滑肌CA I,而血管舒张物质则通过直接作用机制降低了同工酶的活性。体内获得的相同结果表明,血管平滑肌CA I的激活会升高血压,而其抑制则会降低血压。这项研究的结果表明,通过激活或抑制血管平滑肌中的CA I引起的细胞内pH变化可能是血管张力变化的原因。